Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 65Recruiting 35Active not recruiting 27Unknown 25Terminated 17Not yet recruiting 12Withdrawn 5Enrolling by invitation 3Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Esophageal Neoplasms 1

Interventions

Gemcitabine 7Specimen Handling 6Oxaliplatin 5Irinotecan 5S 1 (combination) 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fluorouracil 4Capecitabine 4Biopsy 4Bevacizumab 4Radiotherapy 3Nivolumab 3Immunotherapy 3Drug Therapy 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2titanium silicide 2spartalizumab 2lenvatinib 2aldesleukin 2Taxes 2Surgical Procedures, Operative 2Radiosurgery 2Photochemotherapy 2Interleukin-2 2Endoscopic Mucosal Resection 2Cyclophosphamide 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Carboplatin × Gastrointestinal × Clear all
NCT05191667 2025-02-13

AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Suspended
32 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡